This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

I took the bull by the horns and topped up at 171. In my view we will see 3 again and fairly soon so I just went for it. MMG has too much going for it although I think the shorters still have it. But to quote a well know saying "I'll be back"

MS

Goodnews Guys lifted from another board refering to Evils position evil says...

"All these unpleasant losses and margin calls have prompted me to bank a few gains in Medical Marketing (MMG) at 182p. It is my intention to run a short position as the latest Waanders note and 40p target price is compelling stuff. But given that Medical is fighting hard I see no problem in taking a few coppers off the table" ENDS.

looks like hes beginning to realise theres good news not far off.

Still watching for a few days.

cheers GF.

Great news! I see it as risky, but you got to be innit to winnit, innit?

Things are looking up, well done GF. 3 here we come.

MS

If EK was certain that MMG is so overvalued then why did he close some of his short this AM?. Any sign that he is loosing control and he will be out like a flash.

,,,or maybe he wants to appease the FSA !!!

B

It has been reported that Garry Waanders has resigned.

I'm starting to feel good again. Don't you just feel sorry for Garry.

MS

That is the best news i`ve heard in a long time,he was obviously a total plonker!!!!
db66

If the analyst as resigned its a massive kick in the teeth for Evil K and his buddies. Can anyone confirm where the news comes from????????????.

Ill be back in if this is correct as it should give the stock a massive boost.


cheers GF.

Looks like a recovery this afternoon as i said.

From the other place. A good read. The guys that post on the MMG thread are good and sensible, unlike most of them.

Remember this is not a one product company. Genvax is only the first of MMG's investments to enter phase II clinical trials. And it is only one subsidiary. Let's not lose sight of that fact. Another is Oncosense and its technology based around the precious metal ruthenium. I believe three ruthenium compounds could be going to clinic this year. The prospects for these seem to be absolutely massive.

http://www.platinum.matthey.com/media_room/1107165603.html
Ruthenium cancer treatment proves effective - 31st January 2005

David Best (executive chairman), said the performance of the pgm-based treatment had been verified by independent laboratory tests undertaken by CXR Biosciences, stressing both the safety and the efficacy of the drug.

He explained: "Ruthenium is only one of MMI's portfolio of excellent drug candidates, but already data show it to be potentially the most effective drug against serious cancers like lung, colon and ovarian.

"This new data from CXR shows ruthenium to be potentially relatively safe too. If these results are confirmed in the clinical trials, then ruthenium may improve significantly on the standard treatment for cancer patients and become a major commercial success in a cancer therapy market that was worth $42 billion in 2004 and continues to grow in double-digit figures."

That last sentence is well worth reading again.

And then there are the other subsidiaries of MMG: Viratis and Endozyme, each with potential blockbusters of their own. There is a real chance that these could lead to not one but SEVERAL deals and each one could be worth a multiple of the current market cap of the whole company.

MMG is now capitalised at around 80m. By the end of this year they could have eight drugs in Phase II clinical trials. Success in any one of these will bring big Pharma stepping in for a piece of the action. It's well known that licenses can be worth anything upwards of 100m and have been known to be worth as much as 2bn. But we don't have a precedent for cancer cures yet, these would surely be worth even more.

What value the market cap then??

Institutions were buying in at prices well above 2. They, together with the directors hold the vast majority of shares in the company. I don't believe they will be scared out of them by EK and his like. In fact all the shares sold by small punters recently appear to have been mopped up as well. Just one piece of good news from the company or even a couple of decent brokers notes will send the bears scrambling to cover their shorts. When that will happen is anyone's guess but imo long term holders will be well rewarded.

I hold MMG.

MS

Good post Mickey,im waiting to buy back in,,but i would like to know that EK is out of it.JB..

Again from the other place. This is getting interesting.

Simon Cawkwell - 10 Apr'05 - 10:10 - 4464 of 4689


Gentlemen,

What I cannot understand is DB's failure to contact me - I must be the most approachable man in England. Unless of course he has something to hide.

His claim that I have contributed to a "false market" is risible. He probably does not understand what a false market is - given that he is palpably an uneducated fellow. So he is just putting up a smokescreen by wasting LSE time.

Simon Cawkwell

MS

And Again.

For people's interest.

David Best - Executive Chairman ('Uneducated Fellow'?)

David read medical sciences then statistics and epidemiology at the University of Edinburgh before joining the pharmaceutical industry in 1973. He held senior positions in sales, marketing and business development in Pfizer, Hoechst and Roche. He was a member of the international business development team for biotechnology at Roche before founding MMI in 1988 with Margaret Mitchell.

David was co-founder of Polymer Pharmaceuticals, whose shares were admitted to trading on AIM in 1995 as PolyMASC. He founded the Bioscience Innovation Centre in 1996 which has created, in Cambridge, Europe's first purpose-built, fully-mentored biotechnology business incubator. He is a board member of a number of emerging bioscience businesses including Endozyme, Viratis and Oncosense and he was Chairman, between 1997 and 2000, of CellFactors plc a company developing cell-based therapies for neurodegenerative diseases and skeletal disease. He is also Chairman of the BioStarter Initiative and a member of the London Stock Exchange Advisory Panel for London and the South East.

His other business interests include Healthy Living Centres and he is a board member of Healthy Living (UK) Ltd. He is also Deputy Chairman of the Medical and Scientific Division of the World Fellowship of the Duke of Edinburgh's Award.

MS

There's some good debate going on in the other place. As a lot of you don't go there I thought I would pick the best. Hope it helps

Simon Cawkwell - 10 Apr'05 - 11:35 - 4478 of 4692


tombarr,

Why do you style yourself in the lower case and then venture into capitals? It's a mistake given that the venturing takes you into uncharted (intellectually speaking) territory.

The reason that I used the term "palpably uneducated fellow" is that he has described a state of affairs incorrectly - his use of "false market" is wholly incorrect. An educated fellow - or, at any rate, a fellow evincing signs of having been educated (after all, a fellow could have been very well educated and learnt little or nothing) - would think before opening his mouth. DB does not.

Incidentally, I am interested to know that he is said to be on the LSE Advisory Panel for the SE (or somesuch). This is further evidence of the deadbeats we have to endure in public life.

Simon Cawkwell

MS

Definately an 'uneducated fellow' then. LOL.

Again this says it all. Note the phone number at the end.

Frankly I think your behaviour is an absolute disgrace Mr Cawkwell- please correct me if I am wrong- you have built a large short position in a company and then used a website of which your wife is a shareholder and you have an existing major influence over to distribute a summary of a poorly researched analyst note in an attempt to draw in further sellers and drive the price down and profit for yourself-this was all done without initially declaring to the subscribers and the public at large the short positions already taken out by you and your colleagues. In my book that is frontrunning stock and is almost certainly illegal.

You are not regulated but Mr Winnifrith is and I think that is what people who have been affected by this despicable and unfounded campaign should be concentrating on.

I also find the timely publication of an inaccurate brokers note very interesting- for those who do not know, Gary Waanders is not an expert in the field of specifically cancer "vaccines"- the note should imo opinion have been fully revoked although I suspect KBC could not do that without exposing themselves to major legal action.

You are probably covered by the fact that it is Winnifrith who is reporting your actions and as a result sadly you will probably get away with what can only be described as blatant theft and the fact it is on the back of a company which has just made a major breakthrough in cancer treatment makes it even worse. How do you sleep at night? Dont give me some rubbish about the fact it was overvalued and market forces etc. This was a planned and coordinated attack using clever spin and has suceeded in ripping off genuine shareholders.

I notice there was no mention of MMGs substantial fall in Fridays edition of the UK Analayst Stock Market Report- I wonder why? Are they turing the heat up on T1ps.com? It was surely worthy of a mention. Winnifrith is however as guilty as you imo and I hope they throw the book at him.

If there is a case to be made here of blatant frontrunning stock, I urge everyone on this board who has been affected by this campaign to launch individual complaints to the FSA and LSE and aimed at T1ps.com instead of specifically Cawkwell. The contact details are as follows- 020 7066 4900 and market.abuse@fsa.gov.uk .


MS

And so it goes on. Lots of debate today and Simon is getting a real verbal pasting.

tombarr - 10 Apr'05 - 15:57 - 4525 of 4694


I could not agree more with the comments from 12348 on the potential illegalities.

For those of you wishing to add to Mr Cawkwells impressive list of convictions and censures for things that he claims he hasnt done, please bear in mind that it is the Aim Panel at the London Stock Exchange that regulates this area.

Readers could do worse than to call the LSE General Switchboard 020 7797 1000 first thing Monday morning and register their complaint. Numerous voices do make a difference. Oh, and while you are speaking to the regulator, make sure that you get across the point that the person purporting to be Simon Cawkwell here (and they are certainly related, if not one and the same) has yet again very publicly expressed utter contempt for the effectiveness of that same regulator. Anyone with access to a companies search facility might also like to look into the shareholding and directorship structure of T1ps.com to back up these points, and maybe post that information here as well.

My take is that Mrs Cawkwell, if a shareholder of T1ps.com as claimed here, would be considered a related holder to SC, no matter what he might attempt to spin. 12348 seems pretty much spot on in referring this as front running, not of another trade but in that the short was publicly declared and on (and, SC, I SHOUT again) a REGULATED TIP SITE, after the position was taken - in order to influence the price.

12348: It seems pretty clear that market abuse has likely occurred, and, in the absence of any other action or information it might be entirely reasonable to suspend the stock.

Again, aside from the financial implications, I repeat that I find it highly objectionable that an oncology research company with a raft of maybe life changing products is subject to this kind of low and possibly illegal attack. The fact that SC attempts to dress it up as some sort of intellectual exercise is disingenuous in the extreme - and something that a child could see through. A knock on the door from the boys in blue is well overdue.

MS

Great read MS much obliged.